for tracking institutional and hedge fund stock ownership through 13F filings.
Subscription or paid services:
: Hands down, the best, most complete database of historical clinical trial data and upcoming clinical and regulatory catalysts I've ever used. BioMedTracker is geared toward institutional investors but if you're a serious retail trader or investor, the price pays for itself.
for company and sector financial and valuation data, access to sell-side research, conference call transcripts and full stock-screening capabilities. Another excellent research tool geared toward institutional investors but well worth it, especially if, like me, you're without access to a Bloomberg terminal.
: Real-time stock news, delivered via email. I'm a breaking-news junkie, of course, which makes StreetAccount the most valuable tool in my everyday work toolbox.
Biotech stock research services:
There's a small cottage industry of independent biotech research services out there. Many, thankfully, are priced reasonably enough for retail investors. Learning to do your own research is a great investing skill but the following subscription services, geared toward traders and more fundamentally oriented investors, are definitely worth considering.
Biotech Stock Research
: David Miller and Alan Leong have been doing in-depth, fundamental research on small, development-stage biotechs for a long time. With most sell-side shops abandoning coverage of smallish biotech companies (or covering them only for banking reasons), Miller and Leong's independent research is even more valuable.
Chimera Research Group
: Relative newbies but definite up-and-comers. Chimera does a good job of melding "geek" science research with options and active trading advice. These days, it's hard to make money in biotech investing without a bit of both.
is run by a seasoned biotech trader, Dan Rosenblum, who acts and thinks more like a fundamental investor. It's a profitable mix of skill sets.
is for biotech traders, particularly those who like to trade biotech catalyst events such as FDA drug approvals and pending clinical trial results. Founder Mark Messier knows how to trade biotech stocks and he's built an online community of fellow active traders.
: Tony Pelz is a biotech options-trading guru and a member of the Chimera Research crew.
[Full disclosure: Dan Rosenblum, Mark Messier and Tony Pelz are contributors to <i>TheStreet</i>.]
Other helpful websites:
New England Journal of Medicine
Journal of Clinical Oncology
Biotech Values Message Board
European Medicines Agency
Happy holidays and see you again in 2013.
-- Reported by Adam Feuerstein in Boston.